Vanguard Capital Management
VYGR icon

Vanguard Capital Management’s Voyager Therapeutics VYGR Stock Holding History

Vanguard Capital Management’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.21M Buy
2,345,674
+62,421
+3% +$237K ﹤0.01% 2931
2026
Q1 		$8.81M Buy
+2,283,253
New +$8.99M ﹤0.01% 2800

Other funds holding VYGR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management's VYGR Position: Q2 2026 in Review

Vanguard Capital Management increased its Voyager Therapeutics (VYGR) stake by 2.7% in Q2 2026, buying an estimated $237K and bringing the position to 2,345,674 shares worth $8.21M. The position accounts for ﹤0.01% of the portfolio, ranked #2931.

Vanguard Capital Management first reported a position in VYGR in Q1 2026 and has held it in 2 quarters since. The position peaked at $8.81M in Q1 2026. 136 funds tracked by Wall St. Rank hold VYGR as of Q2 2026.

  • Vanguard Capital Management held 2,345,674 shares of Voyager Therapeutics worth $8.21M as of Q2 2026.
  • Vanguard Capital Management bought 62,421 Voyager Therapeutics shares in Q2 2026, an estimated $237K.
  • Voyager Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2931 holding.
  • Vanguard Capital Management first reported a position in Voyager Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Voyager Therapeutics position peaked at $8.81M in Q1 2026.
  • 136 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.